Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:10:58.027Z.
Calculation as of: 2026-10-06T14:10:58.027Z.
Quote observation: 2026-10-06T14:08:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d3cab615a00e4182867faf392a700f3c2ff11ca91232cb78ad2c83a49f3690
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Bone Biologics Corporation
Market Cap
$898130.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$893920.00
EV/EBITDA Ratio
N/A
TTM Avg
1464.50x
3Y Avg
6462.34x
5Y Avg
6462.34x
Market Cap
$880673.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$814941.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
EV/EBITDA Ratio
N/A
TTM Avg
1.21x
3Y Avg
1.21x
5Y Avg
1.21x
Market Cap
$1.11M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$685794.00
EV/EBITDA Ratio
4.13x
TTM Avg
10.27x
3Y Avg
9.51x
5Y Avg
9.51x
Market Cap
$1.16M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $898130.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | 1464.50x | 6462.34x | 6462.34x |
| Decoy Therapeutics Inc. (DCOY)vs › | $880673.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $814941.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 1.21x | 1.21x | 1.21x |
| Clearmind Medicine Inc. (CMND)vs › | $1.10M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $685794.00 | 4.13x | 10.27x | 9.51x | 9.51x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.16M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.19M | N/A | 18.93x | 18.93x | 18.93x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
